Abstract: The present disclosure provides an inhibitor, represented by formula I, of interaction between YAP/TAZ and TEAD, preparation thereof, a pharmaceutical composition thereof and use thereof. The compound provided in the present disclosure can be used as an inhibitor of interaction between YAP/TAZ and TEAD, and is used for treating or preventing diseases mediated by interaction between YAP/TAZ and TEAD.

Abstract: Provided are bicyclic heteroaryl compounds of Formula (I), methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating cancer and other diseases.

Abstract: Provided is a thermostable glucose oxidase obtained by introducing at least one pair of disulfide bonds into an amino acid sequence of a wild-type Aspergillus niger glucose oxidase or a mutant Aspergillus niger glucose oxidase. The glucose oxidase is suitable for application in the fields of food, chemical engineering, medicine, agriculture and feeds.

Abstract: Provided are compositions for modulating molecules in a cell. Also provided are methods for modulating molecules in a cell.

Abstract: The present invention relates to a NMDA receptor antagonist and use thereof. The NMDA receptor antagonist of the present invention is a compound of formula I below, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a tautomer, a solvate, an isotopic substituent, a polymorphic substance, a prodrug or a metabolite thereof. In the formula, ring A, ring B, and R2 are as described herein. The present invention also provides a pharmaceutical composition comprising these compounds, and use of these compounds in the preparation of a drug for treating or preventing NMDA receptor-mediated diseases.

Abstract: Provided are modulators of androgen receptor (AR) condensates, methods of modulating or inhibiting AR condensates, and methods of treating diseases and conditions using such modulators or inhibitors of AR condensates.

Abstract: Provided are methods for modulating a SRC-1 condensate to regulate transcription of one or more genes, methods of treating diseases and conditions using SRC-1 inhibitors, and methods for screening of agents that modulate SRC-1 condensate.

Abstract: A chimeric lysozyme variant has an improved heat resistance and is encoded by a polynucleotide. A novel chimeric lysozyme sequence is constructed, and high-efficiency expression in a host cell is achieved. The thermal stability of the chimeric lysozyme under the condition of 60° C. is nearly doubled compared to a parental sequence. The chimeric lysozyme variant can be used to prepare product that is antibiotic, for example, animal feed additive containing the chimeric lysozyme variant and an animal feed containing the animal feed additive.

Abstract: Provided is a thermostable glucose oxidase obtained by introducing at least one pair of disulfide bonds into an amino acid sequence of a wild-type Aspergillus niger glucose oxidase or a mutant Aspergillus niger glucose oxidase. The glucose oxidase is suitable for application in the fields of food, chemical engineering, medicine, agriculture and feeds.

Abstract: Disclosed herein is a method for expressing phytase in a filamentous fungus by using an optimized Escherichia coli phytase gene having a nucleotide sequence as shown in SEQ ID NO. 7 and a signal peptide having a nucleotide sequence as shown in SEQ ID NO. 12.

Abstract: The disclosure provides an aminopyrimidine derivative for preventing and treating diseases related to IDH mutation, a preparation method and use thereof. Specifically, the disclosure provides a compound of Formula I, a stereoisomer, racemate thereof, or pharmaceutically acceptable salt thereof. The compound of the general Formula I has isocitrate dehydrogenase 1 (IDH1) inhibitory activity and can treat cancer induced by IDH1 mutation.

Abstract: Disclosed are a compound represented by general formula I and a preparation method therefor. The compound can be used as indoleamine-2,3-dioxygenase inhibitor to prepare medicines for preventing and/or treating indoleamine-2,3-dioxygenase-mediated diseases.

Abstract: Disclosed herein is a method for expressing phytase in a filamentous fungus by using an optimized Escherichia coli phytase gene having a nucleotide sequence as shown in SEQ ID NO. 7 and a signal peptide having a nucleotide sequence as shown in SEQ ID NO. 12.

Abstract: Disclosed are a compound represented by general formula I and a preparation method therefor. The compound can be used as indoleamine-2,3-dioxygenase inhibitor to prepare medicines for preventing and/or treating indoleamine-2,3-dioxygenase-mediated diseases.